In this webinar, join Tony Bou Kheir, PhD, from the Cell and Gene Therapy Catapult in London, as he showcases the Cell and Gene Therapy Catapult’s adeno-associated viruses (AAV) analytical platform and advantages it offers to current industry standards.
Adeno-associated viruses (AAV) are increasingly popular in gene therapy due to their mild immune response, ability to infect a broad range of cells, and overall safety (Naso et al., 2017). Due to the complexity of the delivery vector, a series of robust analytical approaches are required to ensure correct assembly and packaging prior to product release. As the gene therapy field continues to expand and companies increase the number of product batches manufactured per year, the burden on quality control for product release increases significantly. The Cell and Gene Therapy Catapult developed an advanced analytical platform for AAV vector characterization, addressing industry challenges in 1) assay precision through implementation of next generation technologies, 2) standardization and throughout through automation, and 3) enabling in-line product characterization in closed processes through the development of process analytical technologies.
Adeno-associated viruses (AAV) are increasingly popular in gene therapy due to their mild immune response, ability to infect a broad range of cells, and overall safety (Naso et al., 2017). Due to the complexity of the delivery vector, a series of robust analytical approaches are required to ensure correct assembly and packaging prior to product release. As the gene therapy field continues to expand and companies increase the number of product batches manufactured per year, the burden on quality control for product release increases significantly. The Cell and Gene Therapy Catapult developed an advanced analytical platform for AAV vector characterization, addressing industry challenges in 1) assay precision through implementation of next generation technologies, 2) standardization and throughout through automation, and 3) enabling in-line product characterization in closed processes through the development of process analytical technologies.
Speakers:
 |
Tony Bou Kheir, PhD Lead Technical Scientist Cell and Gene Therapy Catapult, London |
||||
| Tony is a molecular biologist experienced in nucleic acid research. He received his PhD from the University of Copenhagen, Denmark. Tony then moved on to London to carry out postdoctoral training at the Barts Cancer Institute, working on epigenetic profiling, gene editing and metabolic targeting of pancreatic cancer stem cells. Since 2017, Tony is working at the Cell and Gene Therapy Catapult in London, focusing on developing analytical methods to supporting AAV manufacture. | |||||
 |
Chris Heger, Ph.D. Senior Manager, Applications Science Bio-Techne |
||||
| Chris is the Senior Manager for the Applications Science group at ProteinSimple. Chris’s group is focused on fostering both external and internal collaborations, creating scientific collateral, and supporting various business units within ProteinSimple. Chris has a broad, in-depth knowledge of immunoassays of many ‘flavors’, capillary electrophoresis, and antibody design, production, and purification. | |||||
 |
Gayathri Kollessery, M.S. Product Manager Bio-Techne |
||||
| Gayathri is the Product Manager for Western Blot Business at ProteinSimple, supporting the Simple Western, Single-cell Western and Imaging product lines. She has a Masters in Genetics, Cell Biology and Anatomy from the University of Nebraska Medical Center. Her background includes support of high throughput systems used in both Clinical and Research segments. | |||||
